Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

Prior treatment

• 2\. Known premixed insulin or IDegAsp used 3 month before randomization;
• 5\. Cardiovascular and cerebrovascular disease, defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, stroke and/or myocardial infarction within 6 months before screening; or planned/coronary artery , carotid artery, peripheral artery revascularization;
• 10\. Two or more events of ketoacidosis or hyperglycemia and hyperosmolar state requiring hospitalization within 6 months prior to screening, or significant diabetic complications, such as symptomatic autonomic neuropathy, diabetic gastric mildew paralysis, proliferative retinopathy, etc. occured;
• 12\. Pregnant or breastfeeding women; those who have a pregnancy plan during the entire trial period and are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial;
• 14\. Those who are not suitable to participate in the trial according to the investigator's judgment, or any clinically significant disease or condition that the investigator believes may affect the results of the trial, such as: a history of hemolytic anemia or sickle cell anemia, a previous history of tumor or cancer Patients with a medical history, patients with a known history of alcohol, drug or drug abuse, blood transfusions or severe blood loss within the first 3 months of screening, or patients with poor adherence in the judgment of the investigator.

Other illness

• 1\. Suffering from type 1 diabetes, or special type of diabetes;
• 4\. Known or suspected subjects are allergic to test drugs, excipients or related similar products and excipients;
• 6\. According to the judgment of the investigator, repeated hypoglycemia perception impairment and severe hypoglycemia events occurred before screening;
• 9\. Uncontrolled/untreated hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) before randomization;

Lab values

• 3\. Changes in concomitant medications that are expected to significantly interfere with glucose metabolism;
• 7\. Abnormal and clinically significant hemoglobin laboratory test results;
• 8\. Hepatic insufficiency, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times the upper limit of the normal range at screening; renal insufficiency, defined as (but not limited to) serum creatinine Levels ≥1.5mg/dL (132umol/L, men) and ≥1.4mg/dL (123umol/L, women), or massive proteinuria (\>2 g/day);

Other

• 11\. According to the judgment of the investigator, significant changes in lifestyle are expected during the trial period, such as shift work (including persistent night/evening shift work) and highly irregular diet and living habits;
• 13\. Participate in any clinical trial within the past 3 months;

• 1\. Informed consent has been obtained before any trial-related activities;
• 2\. Patients aged 18\~75 years old (including 18 years old and 75 years old);
• 3\. Clinical diagnosis of type 2 diabetes ≥ 6 months according to WHO diagnostic criteria before screening;
• 4\. Use basal insulin once a day with or without other hypoglycemic drugs for at least 3 months before randomization;
• 5\. Glycated hemoglobin between 7.0%\~10.0% within 3 month before randomization (including the critical value);
• 6\. Body mass index (BMI)≤40.0kg/m2;